Canadian probe ends into drug makers accused of stifling competition by generics

The Competition Bureau has ended its investigation into three name brand drug companies that are accused of hampering their generic rivals by restricting access to samples of their patented drugs needed for testing. The bureau concluded Celgene, Pfizer and Sanofi did not contravene the Competition Act.